Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin and ankle-foot orthosis for post-stroke knee hyperextension
ACTRN12609000034235Phase 4Recruiting
- Sponsor
- Clinical Gait Analysis Service
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of botulinum toxin type A and Normal Saline-Benha University in stroke (3 arms), sponsored by Clinical Gait Analysis Service. Primary endpoints: Decrease in knee hyperextension during stance and Increase in ankle dorsiflexion range of motion. Started Feb 2009; status: recruiting.
02
Drugs
botulinum toxin type ANormal Saline-Benha University
03
Conditions
stroke
Beyond the preview
Go deeper on ACTRN12609000034235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000034235.